XDR-TB Can Be Treated

More than 60 percent of HIV-negative XDR -TB patients in the study, which was conducted in home and community-based settings in Peru...

Once thought to be incurable, extensively drug-resistant tuberculosis (XDR-TB) can be treated in some patients, if they are not co-infected with HIV and have access to comprehensive care, according to a study published in the August 7 issue of the New England Journal of Medicine (NEJM). More than 60 percent of HIV-negative XDR -TB patients in the study, which was conducted in home and community-based settings in Peru between 1999 and 2002, were successfully treated using a combination of free, individualized drug treatment and additional services, such as surgery, adverse-event management, and nutritional and psychological support.

"It's essential that the world know that XDR-TB is not a death sentence," says lead author Carole Mitnick, a Harvard Medical School instructor in global health and social medicine. The results from Peru, which were even better than some XDR-treatment results in hospitals in Europe, the United States, and Korea, demonstrate that even in settings where there are limited resources, XDR-TB can be cured in many cases on an outpatient basis.

Writing in the same issue of NEJM, Mario C. Raviglione, head of the Stop TB Department of the World Health Organization, praised the study for changing the perception that XDR-TB is untreatable. He cautioned, however, that the high rate of successful treatment in Peru may not be reproducible elsewhere; a strain of XDR-TB reported in Italy, for example, is resistant to all available drugs. And the local capacity for TB treatment in Peru may be exceptional, because it results from cooperation among HMS, the Harvard School of Public Health, Brigham and Women's Hospital, the Massachusetts State Laboratory Institute, and the Lima, Peru-based organizations Socios en Salud, the Hospital Nacional Sergio Bernales, and the Peruvian Ministry of Health.

The question and the challenge now, writes Raviglione, is whether this model of treatment can be scaled up—not just nationally in Peru, but globally.

For more about the global threat of tuberculosis, see "A Plague Reborn."

 

 

 

Related topics

You might also like

A Flu Vaccine That Actually Works

Next-gen vaccines delivered directly to the site of infection are far more effective than existing shots.

What Happens When Infections Stop Responding to Antibiotics?

Harvard Medical School experts discuss the growing threat of antimicrobial resistance.

Green AI: Hype or Hope?

An expert panel explores AI’s climate impact, from emissions to water use.

Most popular

What Trump Means for John Roberts's Legacy

Executive power is on the docket at the Supreme Court.

The Harvard Professor Who Quantified Democracy

Erica Chenoweth’s data shows how—and when—authoritarians fall.

Three Harvardians win MacArthur Fellowships

A mathematician, a political scientist, and an astrophysicist are honored with “genius” grants for their work.

Explore More From Current Issue

Two small cast iron pans with berry-topped desserts, dusted with powdered sugar, alongside lemon slices.

Shopping for New England-made gifts this Holiday Season

Ways to support regional artists, designers, and manufacturers 

A diverse group of adults and children holding hands, standing on varying levels against a light blue background.

Why America’s Strategy For Reducing Racial Inequality Failed

Harvard professor Christina Cross debunks the myth of the two-parent Black family.

Six women interact in a theatrical setting, one seated and being comforted by others.

A (Truly) Naked Take on Second-Wave Feminism

Playwright Bess Wohl’s Liberation opens on Broadway.